BRIMONIDINE P SOLUTION

Χώρα: Καναδάς

Γλώσσα: Αγγλικά

Πηγή: Health Canada

Δραστική ουσία:

BRIMONIDINE TARTRATE

Διαθέσιμο από:

AA PHARMA INC

Φαρμακολογική κατηγορία (ATC):

S01EA05

INN (Διεθνής Όνομα):

BRIMONIDINE

Δοσολογία:

0.15%

Φαρμακοτεχνική μορφή:

SOLUTION

Σύνθεση:

BRIMONIDINE TARTRATE 0.15%

Οδός χορήγησης:

OPHTHALMIC

Μονάδες σε πακέτο:

5ML/10ML

Τρόπος διάθεσης:

Prescription

Θεραπευτική περιοχή:

ALPHA-ADRENERGIC AGONISTS

Περίληψη προϊόντος:

Active ingredient group (AIG) number: 0131859003; AHFS:

Καθεστώς αδειοδότησης:

APPROVED

Ημερομηνία της άδειας:

2008-07-15

Αρχείο Π.Χ.Π.

_BRIMONIDINE P (Brimonidine Tartrate ophthalmic solution) _
_Page 1 of 30 _
PRODUCT MONOGRAPH
INCLUDING PATIENT MEDICATION INFORMATION
Pr
BRIMONIDINE P
Brimonidine Tartrate ophthalmic solution
Sterile Solution, 0.15% w/v, for ophthalmic use
Relatively Selective α
2
-Adrenoceptor Agonist
ATC code: S01EA05
AA PHARMA INC
1165 Creditstone Road, Unit #1
Vaughan, Ontario
L4K 4N7
Date of Initial Authorization:
July 15, 2008
Date of Revision:
August 29, 2023
Submission Control Number: 273876
_BRIMONIDINE P (Brimonidine Tartrate ophthalmic solution) _
_Page 2 of 30 _
RECENT MAJOR LABEL CHANGES
None at the time of the most recent authorization.
TABLE OF CONTENTS
SECTIONS OR SUBSECTIONS THAT ARE NOT APPLICABLE AT THE TIME OF
AUTHORIZATION ARE NOT LISTED.
RECENT MAJOR LABEL CHANGES
...........................................................................................
2
TABLE OF CONTENTS
.............................................................................................................
2
PART I: HEALTH PROFESSIONAL INFORMATION
.....................................................................
4
1
INDICATIONS
..................................................................................................................
4
1.1
Pediatrics
.................................................................................................................
4
1.2
Geriatrics
..................................................................................................................
4
2
CONTRAINDICATIONS
.....................................................................................................
4
4
DOSAGE AND ADMINISTRATION
.....................................................................................
4
4.1 Dosing Considerations
......................................................................................................
4
4.2 Recommended Dose and Dosage Adjustment
................................................................. 5
4.4 Administration
...................................